Alicia Morgan, MD, MPH on real-world data from the DEAR study.

S4 Ep14: First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC

<div>Targeted Oncology brings you <em>Treating Together</em>, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.</div>

Science

Health & Fitness

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Targeted Oncology brings you <em>Treating Together</em>, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Share S4 Ep14: First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC

Sign up to save your podcasts

S4 Ep14: First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC

S4 Ep14: First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC

More shows like Treating Together

Planet Money

Interesting Times with Ross Douthat